Literature DB >> 12865450

Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.

Scott D Cramer1, Bao-Li Chang, Anuradha Rao, Gregory A Hawkins, S Lilly Zheng, Wendy N Wade, Roger T Cooke, Leanne N Thomas, Eugene R Bleecker, William J Catalona, David A Sterling, Deborah A Meyers, Jill Ohar, Jianfeng Xu.   

Abstract

BACKGROUND: Recent evidence suggests that genetic variation in the promoter of the prostate-specific antigen (PSA) gene may contribute to individual variation in serum PSA levels. However, polymorphisms associated with variations in PSA levels have not been identified.
METHODS: We used the polymerase chain reaction to amplify the promoter region of the PSA genes (nucleotide positions -3873 to -5749 with respect to the start of transcription) of 409 healthy white men at risk for lung disease. Polymerase chain reaction products were sequenced to identify polymorphisms in the PSA gene promoter and to genotype the men for common single nucleotide polymorphisms (SNPs) and were cloned into luciferase reporter constructs to assay PSA promoter activity in human LNCaP prostate cancer cells. Analysis of variance was used to test the association of polymorphism frequencies with mean serum PSA levels. All statistical tests were two-sided.
RESULTS: The -4643G/A SNP (G allele) had a 21.2% prevalence and was associated with increases in serum PSA levels (P =.017) and PSA promoter activity (P<.001). The -5412C/T SNP (C allele) had a 22.0% prevalence and was associated with an increase in serum PSA levels (P =.0015). The -5429T/G SNP (G allele) had a 23.0% prevalence, was associated with an increase in serum PSA levels (P =.021), and was in linkage disequilibrium with the -5412C/T SNP. The promoter activity of the -5412 C/-5429 G haplotype was higher than that of the -5412 T/-5429 T haplotype (P<.001).
CONCLUSIONS: Genetic variations in the PSA promoter are associated with serum PSA levels in men without prostatic disease. PSA promoter genotype information may help to refine models of PSA cutoff values.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865450     DOI: 10.1093/jnci/95.14.1044

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  29 in total

1.  Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Guangyun Sun; Ritesh Kaushal; Joshua J Meeks; C Shad Thaxton; Saurav Guha; Carol H Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2007-06-26       Impact factor: 4.132

2.  Re: Nadler RB, McNaughton Collins M, Propert KJ, et al: Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome (Urology 67: 337-342, 2006).

Authors:  Jordan D Dimitrakov
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

3.  Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy.

Authors:  Sung Woon Park; Chul Sung Kim; Gilho Lee
Journal:  Korean J Urol       Date:  2010-12-21

4.  Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.

Authors:  Mark M Pomerantz; Lillian Werner; Wanling Xie; Meredith M Regan; Gwo-Shu Mary Lee; Tong Sun; Carolyn Evan; Gillian Petrozziello; Mari Nakabayashi; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-02

5.  Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma.

Authors:  Venkat R Katkoori; Xu Jia; Chakrapani Chatla; Sanjay Kumar; Selvarangan Ponnazhagan; Tom Callens; Ludwine Messiaen; William E Grizzle; Upender Manne
Journal:  Front Biosci       Date:  2008-01-01

6.  Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.

Authors:  Brian T Helfand; Stacy Loeb; Qiaoyan Hu; Phillip R Cooper; Kimberly A Roehl; Barry B McGuire; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2013-02-27       Impact factor: 7.450

7.  Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer.

Authors:  Scott D Cramer; Jielin Sun; S Lilly Zheng; Jianfeng Xu; Donna M Peehl
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

8.  A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (KLK) locus.

Authors:  Carolyn A Goard; Irvin L Bromberg; Marc B Elliott; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 9.  Natriuretic peptides in the diagnosis and management of chronic heart failure.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Clin       Date:  2009-10       Impact factor: 3.179

10.  A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33.

Authors:  Hemang Parikh; Zuoming Deng; Meredith Yeager; Joseph Boland; Casey Matthews; Jinping Jia; Irene Collins; Ariel White; Laura Burdett; Amy Hutchinson; Liqun Qi; Jennifer A Bacior; Victor Lonsberry; Matthew J Rodesch; Jeffrey A Jeddeloh; Thomas J Albert; Heather A Halvensleben; Timothy T Harkins; Jiyoung Ahn; Sonja I Berndt; Nilanjan Chatterjee; Robert Hoover; Gilles Thomas; David J Hunter; Richard B Hayes; Stephen J Chanock; Laufey Amundadottir
Journal:  Hum Genet       Date:  2009-10-13       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.